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ttp://dx.doi.org/10.1016/j.ajpath.2013.11.027Polycystic liver disease (PLD) is a member of the cholangiopathies, a group of liver diseases in which
cholangiocytes, the epithelia lining of the biliary tree, are the target cells. PLDs are caused by mu-
tations in genes involved in intracellular signaling pathways, cell cycle regulation, and ciliogenesis,
among others. We previously showed that cystic cholangiocytes have abnormal cell cycle proﬁles and
malfunctioning cilia. Because histone deacetylase 6 (HDAC6) plays an important role in both cell cycle
regulation and ciliary disassembly, we examined the role of HDAC6 in hepatic cystogenesis. HDAC6
protein was increased sixfold in cystic liver tissue and in cultured cholangiocytes isolated from both PCK
rats (an animal model of PLD) and humans with PLD. Furthermore, pharmacological inhibition of HDAC6
by Tubastatin-A, Tubacin, and ACY-1215 decreased proliferation of cystic cholangiocytes in a dose- and
time-dependent manner, and inhibited cyst growth in three-dimensional cultures. Importantly, ACY-
1215 administered to PCK rats diminished liver cyst development and ﬁbrosis. In summary, we show
that HDAC6 is overexpressed in cystic cholangiocytes both in vitro and in vivo, and its pharmacological
inhibition reduces cholangiocyte proliferation and cyst growth. These data suggest that HDAC6 may
represent a potential novel therapeutic target for cases of PLD. (Am J Pathol 2014, 184: 600e608;
http://dx.doi.org/10.1016/j.ajpath.2013.11.027)Supported by Mayo Clinic Center for Cell Signaling in Gastroenterology
Pilot and Feasibility Award P30DK084567 (S.A.G.), R21 R21CA166635
(S.A.G.), and R01 DK24031 (N.F.L.).
Disclosures: None declared.The polycystic liver diseases (PLDs) are genetic disorders
that can be included in the cholangiopathies, a group of
diseases of diverse etiologies, all of which have the chol-
angiocyte as the target cell. PLDs occur either alone or
together with polycystic kidney disease (PKD).1
Mutations in the PRKCSH (protein kinase C substrate
80K-H) and Sec63 genes lead to autosomal dominant poly-
cystic liver disease without kidney involvement by affecting
the cell’s post-translational protein modiﬁcation machinery
and ciliary signal transduction via polycystin-2 degrada-
tion.2e5Mutations in thePkd1 andPkd2 genes, which encode
the ciliary-associated proteins, polycystin-1 and polycystin-2,
are causative for cystic degeneration of the liver and kidneys
in autosomal dominant polycystic kidney disease (ADPKD),
whereas a mutated form of ﬁbrocystin, encoded by the Pkhd1
gene, is found in autosomal recessive polycystic kidney dis-
ease (ARPKD).6e9
Formation and growth of hepatic cysts lined by chol-
angiocytes is the key feature of PLD, a process in which several
intracellular signals, including calcium, and cAMP signalingstigative Pathology.
.are involved.10e13 Cystic cholangiocytes also have malformed
cilia and overexpression, and mislocalization of solute and
water transporters involved in cholangiocyte bile secretion.14,15
These molecular alterations increase the rate of cholangiocyte
proliferation and secretion leading to cyst growth.15,16
Recent studies have shown a positive effect of the pan-
histone deacetylase (HDAC)-inhibitor Trichostatin A (TSA)
and the class I HDAC inhibitor, valproic acid (VPA), on cyst
development in kidneys of an animal model of ADPKD.17,18
HDACs are a heterogeneous group of enzymes organized in
classes I to IV, which have multiple functions, including
epigenetic regulation of transcription via histone deacetyla-
tion. Among these HDACs, the mostly cytoplasmic histone
deacetylase 6 (HDAC6) regulates Wnt-signaling by deace-
tylating b-catenin, enabling its cytosolic accumulation and
HDAC6 in Polycystic Liver Diseasesnuclear translocation, where it activates transcription and
cell-cycle progression.19 Furthermore, HDAC6 is involved in
the resorption of cilia in tumor cells by deacetylation of mi-
crotubules forming the ciliary axoneme.20
Therefore, we assessed the potential role of HDAC6 in
hepatic cystogenesis. We measured HDAC6 protein ex-
pression in cystic cholangiocytes of rodents and humans
with PLD and evaluated the effects of the HDAC6-specifc
inhibitors, Tubastatin-A, (ChemieTek, Indianapolis, IN)
Tubacin, and ACY-1215 on cholangiocyte proliferation and
cyst growth both in vitro and in vivo. To begin under-
standing the potential mechanisms underlying the effect of
HDAC6 inhibitors on cystic cholangiocytes, downstream
effector molecules such as acetylated a-tubulin and b-cat-
enin were also tested after HDAC6 inhibition.
Materials and Methods
Tissue Culture
For in vitro experiments, we used cholangiocytes isolated
from control rats, PCK rats (an animal model for ARPKD),21
healthy humans and ADPKD patients.22e24 Cholangiocytes
were cultured in Collagen-I-coated ﬂasks (BD BioCoat, San
Jose, CA). All cell lines mentioned were incubated in NRC
Media at 37C, 5% CO2, 100% humidity. NRC Media
contains Dulbecco’s modiﬁed Eagle’s medium/F12 with the
following additions: 0.01 mL/mL minimum essential media
nonessential amino acids, 0.01 mL/mL lipid concentrate,
0.01 mL/mL minimum essential media vitamin solution, 2
mmol/L L-glutamine, 0.05 mg/mL soybean trypsin inhibi-
tor, 0.01 mL/mL insulin/transferring/selenium-S, 5% fetal
bovine serum, 30 g/mL bovine pituitary extract, 25 ng/mL
epidermal growth factor, 393 ng/mL dexamethasone, 3.4 g/
mL 3,30,5-triiodo-L-thyronine, 4.11 g/mL forskolin, and 1%
penicillin-streptomycin.
Western Blots
Protein isolated from at least three separate cultures of
control and PCK rat cholangiocytes were used. Cells were
scrapped, resuspended in PBS (with protease inhibitors,
sodium orthovanadate, and phenylmethanesulfonyl ﬂuo-
ride), sonicated, and then diluted in Laemmli sample buffer
(Bio-Rad, Hercules, CA) and mercaptoethanol with equal
amounts of sample protein. After SDS-PAGE, proteins were
transferred to nitrocellulose membranes, blots were blocked,
and then incubated with the following primary antibodies:
HDAC6 (D-11, 1:500; Santa Cruz Biotechnology, Santa
Cruz, CA), acetylated-a-tubulin (1:2000; Sigma-Aldrich, St.
Louis, MO), b-catenin[(D10A8) XP rabbit mAb (1:1000);
Cell Signaling Technology, Danvers, MA], phospho-b-cat-
enin (Ser33/37/Thr41) (1:1000; Cell Signaling Technology),
acetyl-b-catenin (K49) (1:1000; Cell Signaling Technol-
ogy), c-myc (1:500; Santa Cruz Biotechnology), cyclin D1
(1:500; Santa Cruz Biotechnology), and actin (1:5000;The American Journal of Pathology - ajp.amjpathol.orgSigma-Aldrich). The membranes were incubated overnight
at 4C, washed and incubated for 1 hour at room tem-
perature with horseradish perodixase-conjugated (1:5000;
Invitrogen, Camarillo, CA) or IRdye 680 or 800 (1:15,000;
LI-COR, Lincoln, NE) corresponding secondary antibody.
The enhanced chemiluminescence (ECL; Pierce Biotech-
nology, Rockford, IL) system or Odyssey LI-COR Scanner
was used for protein detection and the Gel-Pro Analyzer
software version 6.0 (Media Cybernetics, Inc., Rockville,
MD) was used for densitometry analysis.
Proliferation Assays
Control and PCK rat cholangiocytes were cultured on
Collagen-I-coated ﬂasks (BD BioCoat) using NRC Media,
detached with 0.25% trypsin-EDTA (Gibco, Invitogen Corp,
Carlsbad, CA), transferred to collagen-I-coated 96-well plates
(10,000 cells/well), and incubated at 37C, 5% CO2, 100%
humidity. Treatment with 5, 10 and 20 mmol/L Tubastatin-A
(ChemieTek), 1 to 2 mmol/L Tubacin (ChemieTek), or 2, 4,
and 8 mmol/L ACY-1215 (generously provided by Acetylon
Pharmaceutical, Inc., Boston, MA) suspended in NRC media
was started 24 hours later. The drug vehicle, dimethyl sulf-
oxide, was suspended in NRC media as a control. Cell pro-
liferation was assessed with the CellTiter 96 AQueous One
Solution (MTS; Promega,Madison,WI) and/or counting cells
using the Cellometer Auto T4 Cell Counter (Nexcelom
Bioscience, Lawrence, MA).
Immunoﬂuorescence and Confocal Microscopy
Parafﬁn-embedded liver sections of control (n Z 3) and
PCK (n Z 4) rats, healthy humans, and ADPKD and
ARPKD patients were incubated with antibodies against
HDAC6 (D-11, 1:100; Santa Cruz Biotechnology) and
acetylated-a-tubulin (mouse monoclonal 1:500; Sigma-
Aldrich) overnight at 4C followed by 90 minutes at room
temperature of ﬂuorescent secondary antibody incubation.
Nuclei were stained with DAPI (ProLong Gold Antifade
Reagent; Life Technologies, Carlsbad, CA). Images were
acquired with a Zeiss LSM 510 confocal microscope (Carl
Zeiss Inc., Thornwood, NY). Parafﬁn blocks from 3 normal,
3 ARPKD, and 3 ADPKD patients were obtained from the
Mayo Clinic Tissue Registry Archives. All experimental
procedures were approved by the Mayo Clinic Institutional
Review Boards (Institutional Review Board no. 08-005681).
PCR
RNA was isolated from control and PCK rat cholangiocytes
with TRIZOL reagent (Invitrogen). The cDNA was obtained
using First Srand cDNA Synthesis (Invitrogen) reagents and
HDAC6 primers (forward primer: 50-TCAGCGCAGTCT-
TATGGATG-30; reverse primer: 50-GCGGTGGATGGA-
GAAATAGA-30), which were purchased from Integrated
DNA Technologies (Coralville, IA). b-catenin mRNA601
Gradilone et alexpression was analyzed using the TaqMan Gene Expres-
sion Assay (Assay ID Rn00584431_g1) following the
manufacturer’s directions. The samples were normalized to
18S rRNA.
Three-Dimensional Culture
Freshly isolated bile ducts from the PCK rat were embedded in
a rat-tail type I Collagen matrix (BD Biosciences, San Jose,
CA) and grown in the presence or absence of 10 mmol/L
Tubastatin-A and 2 mmol/L Tubacin. Images of the growing
cysts were taken every day within a period of 5 days and cyst
size was measured with ImageJ software version 1.46r (NIH,
Bethesda, MD). We compared circumferential areas for each
cystic structure to day 0 to calculate percentages of growth as
previously described.25e28
In Vivo Experiments
For in vivo experiments, 3-week-old PCK rats were injected
daily intraperitoneally during 4 weeks with 30 mg/kg body
weight ACY-1215 (kindly provided by Acetylon Pharma-
ceuticals, Inc.) or vehicle. All experimental procedures were
approved by the Animal Use and Care Committee of the
Mayo Clinic. At the end of the treatment, rats were sacri-
ﬁced and body, liver, and kidney weights were assessed.
Because no signiﬁcant differences were found between
sexes, we grouped the animals for statistical analysis.
Hepatorenal cystic and ﬁbrotic areas were assessed using
liver and kidney sections stained with picrosirius red. Both
the cystic and ﬁbrotic areas were measured using the
MetaMorph Imaging software (Molecular Devices, Inc.,
Downingtown, PA), and data were expressed as a percent-
age of the total parenchyma, as previously described.26,28
Statistics
Data are expressed as means  SEM. Statistical analyses
were conducted by two-tailed Student’s t-tests to compare
two groups. The cut-off P value for signiﬁcance was set at
P < 0.05.
Results
HDAC6 Is Overexpressed in Cystic Cholangiocytes
First, to assess the expression of Hdac6 mRNA in chol-
angiocytes, PCR using mRNA isolated from cultured rat
cholangiocytes was performed. As shown in Figure 1A,
Hdac6 mRNA is present in both control and PCK rat chol-
angiocytes. The identity of the PCR product was conﬁrmed
by sequencing. Using Western blot analysis, we found that
Hdac6 protein is overexpressed 6.5-fold in PCK chol-
angiocytes compared to control rat cholangiocytes, and
Hdac6 overexpression correlated with decreased levels of
acetylated-a-tubulin, one of the main Hdac6 substrates602(Figure 1B).29 The overexpression of Hdac6 observed in vitro
was conﬁrmed in vivo by confocal immunoﬂuorescence of
liver tissues. In the liver tissues of PCK rats, and ADPKD and
ARPKD patients, we found that the immunoreactivity of
HDAC6was increased in hepatic cysts comparedwith normal
rats and healthy human controls, respectively (Figure 1C).
Inhibition of HDAC6 Decreases Cholangiocyte
Proliferation and Cysts Growth in Vitro
Wepreviously showed that PCK cholangiocytes proliferate at
a higher rate than control rat cholangiocytes.13 We tested our
hypothesis that up-regulation of HDAC6 contributes to
cholangiocyte hyperproliferation by applying the HDAC6
selective inhibitor Tubastatin-A to cultured cholangiocytes.
Indeed, this drug decreased PCK cholangiocyte proliferation
in a dose- and time-dependent fashion (Figure 2A). By day 3,
proliferation of treated PCK cholangiocytes was reduced by
2.5-, 3.5-, and 4.15-folds for 5 mmol/L, 10 mmol/L and 20
mmol/L Tubastatin-A, respectively. Additionally, a different
HDAC6 speciﬁc inhibitor, Tubacin, also reduced PCK chol-
angiocyte proliferation by 2.94-folds (Figure 2B). Both drugs
also decreased proliferation of cultured human ADPKD
cholangiocytes by 85% and 16%, respectively (Supplemental
Figure S1A). To further conﬁrm the effect of HDAC6 inhi-
bition on proliferation, we used the Cellometer Auto T4 Cell
Counter (Nexcelom Bioscience) and conﬁrmed that the
HDAC6 Inhibitor Tubastatin-A signiﬁcantly reduces cystic
cholangiocyte proliferation (Supplemental Figure S1B).
Finally, liver cysts isolated from the PCK rat were grown in a
three-dimensional collagen matrix and treated with HDAC6
inhibitors (Figure 2C). Analysis of the circumferential areas
of the PCK cystic structures showed signiﬁcant inhibition of
cyst growth. After 4 days of drug administration, Tubastatin-
A and Tubacin reduced cyst growth by 131% and 125%,
respectively, compared with untreated cysts (Figure 2D).
Inhibition of HDAC6 Correlates with a Decrease in
b-Catenin Protein Level
For a better understanding of the mechanisms that are
responsible for the inhibition of PCK cholangiocyte pro-
liferation and cyst growth in three-dimensional culture, we
treated cultured PCK cholangiocytes with Tubastatin-A
and Tubacin, and we determined the amount of acetylated
a-tubulin and b-catenin by using Western blot analysis.
As expected, PCK cholangiocytes treated with Tubastatin-
A and Tubacin had increased levels of acetylated a-
tubulin (13- and 2.3-fold) compared with untreated cells
(Figure 3A). In contrast, the levels of b-catenin were
decreased by 2.2-fold, and ﬁvefold after treatment with
Tubastatin-A and Tubacin, respectively (Figure 3A).
Furthermore, immunoﬂuorescence analysis of b-catenin
subcellular localization also demonstrated decreased
expression both in nuclei and cytoplasm induced by
HDAC6 inhibition (Supplemental Figure S2). Consistentajp.amjpathol.org - The American Journal of Pathology
Figure 1 HDAC6 is overexpressed in cystic
cholangiocytes. A: PCR analysis showing HDAC6
mRNA expression in both normal cells (NRC)
and PCK rat cholangiocytes. B: Representative
of Western blots for HDAC6 and acetylated
a-tubulin expression in NRC and PCK rat chol-
angiocytes and densitometric analysis of the
Western blot analysis results (nZ 3 for control;
nZ 4 for PCK). C: Immunoﬂuorescence confocal
microscopy of liver cysts in PCK rats (n Z 5),
human ADPKD (n Z 3), ARPKD (n Z 3) livers,
and respective controls (nZ 5 and 3 for rats and
humans, respectively). HDAC6 is green, CK19 is
red, and nuclei are blue (DAPI). *P < 0.05.
HDAC6 in Polycystic Liver Diseaseswith b-catenin reduction, HDAC6 inhibition induced a
decrease in the b-catenin gene target products cyclin D1
and c-myc, while the levels of acetylated histone H3
remained unaffected (Figure 3A). Furthermore, HDAC6The American Journal of Pathology - ajp.amjpathol.orginhibition induced increased b-catenin acetylation at Lys49
and phosphorylation at Ser33, Ser37, and/or Thr41
(Figure 3B), consistent with b-catenin destabilization and
targeting to degradation, as previously described.19,30603
Figure 2 Pharmacological inhibition of HDAC6
decreases cystic cholangiocyte proliferation and
cystic growth. Cells were incubated in 96-well
plates and proliferation was analyzed by MTS
assay. A: PCK rat cholangiocytes proliferation over
time with different doses of Tubastatin-A. B: PCK
rat cholangiocytes after 3 days of proliferation. C:
Representative images of biliary cysts freshly iso-
lated from PCK rats. The cysts were embedded in rat
tail collagen matrix and treated with two different
HDAC6 speciﬁc inhibitors, Tubastatin-A and Tuba-
cin. D: Quantitative analysis of cyst growth over
time (nZ 12 for 10 mmol/L Tubastatin-A; nZ 4 for
2 mmol/L Tubacin; nZ 16 for untreated controls).
Original magniﬁcation 40 (C) (*P < 0.05).
Gradilone et alb-catenin protein decreases over time when cells have
been treated with the HDAC6 inhibitor, whereas the levels
of b-catenin mRNA remain stable, suggesting that HDAC6
inhibition induces the degradation of b-catenin protein
(Figure 3C).
The Speciﬁc HADC6 Inhibitor ACY-1215 Decreases Cyst
Formation in Vivo
To further assess the potential role of HDAC6 inhibition as
a potential therapeutic approach for PLD, we evaluated theFigure 3 HDAC6 inhibitors increase acetylated a-tubulin and decrease b-cate
Tubacin were lysed and used for Western blot analysis. A: Representative images
sentative images of Western blots (nZ 3). Total-b-catenin was used as a loading
2 mmol/L Tubacin.
604effect of the recently developed, orally bioavailable drug,
ACY-1215.31 First, we assessed the effect of ACY-1215 in
the proliferation rates of normal and PCK cholangiocytes.
ACY-1215 inhibited PCK cells proliferation in a dose-
dependent manner and had no signiﬁcant effect on prolif-
eration of normal cells (Figure 4A). Then, we tested the
effect of the drug in vivo, using the PLD animal model, the
PCK rat. We found a signiﬁcant reduction in both the liver
and kidney cyst area [by 28.4% and 39.0%, respectively
(Figure 4, B and C)]. Importantly, liver ﬁbrosis was also
reduced by 30.5% (P < 0.001).nin. PCK cholangiocytes treated with 20 mmol/L Tubastatin-A or 2 mmol/L
of Western blots (n Z 3). Actin was used as a loading control. B: Repre-
control. C: Western blots and RT-PCR analysis over time after treatment with
ajp.amjpathol.org - The American Journal of Pathology
Figure 4 ACY-1215 inhibits cyst growth in vivo. A: Proliferation assays
on normal cells (NRCs) and cystic cholangiocytes (PCKs) incubated in the
presence of different doses of AYC-1215. B: Representative liver and kidney
sections stained with picrosirius red from PCK rats treated with vehicle
(n Z 8) or ACY-1215 (n Z 8). C: Quantiﬁcation analysis of cystic area
expressed as percentage of total parenchyma area (*P < 0.05).
HDAC6 in Polycystic Liver DiseasesDiscussion
Our key ﬁndings relate to the potential role of HDAC6 in
the pathogenesis of cystic liver disease. We showed that:
i) HDAC6 protein is overexpressed in cultured PCK rat and
ADPKD and ARPKD cholangiocytes, ii) inhibition of
HDAC6 with Tubastatin-A, Tubacin, or ACY-1215 de-
creased proliferation of both cultured PCK rat chol-
angiocytes and human ADPKD cultured cholangiocytes in a
time- and dose-dependent fashion, iii) pharmacological in-
hibition of HDAC6 reduced proliferation of cystic bile ducts
isolated from the PCK rat and cultured in a three-
dimensional collagen matrix, iv) HDAC6 inhibition in-
creases the expression of acetylated-a-tubulin and decreases
the expression of b-catenin, and v) pharmacological inhi-
bition of HDAC6 reduced liver and kidney cyst growth in
an animal model of PLD. Taken together, our data suggest
that HDAC6 plays a potential role in the development
of liver cysts and its pharmacological inhibition reduces
cystic growth by a mechanism that may involve inhibition
of b-catenin.
HDAC6 overexpression in cholangiocytes of these
benign hyperproliferative diseases, both in the PCK rat and
in human ADPKD and ARPKD, is in agreement with the
overexpression reported in cystic kidneys of the ADPKD
mice model, pkd1 mutant.32 Furthermore, HDAC6 over-
expression is consistent with the observed reduction of one
of its main targets, acetylated-a-tubulin (Figure 1B). How-
ever, to our knowledge, this is the ﬁrst report of HDAC6
overexpression in PLD.
The mechanisms underlying HDAC6 overexpression
remain to be elucidated, but potential mechanisms mayThe American Journal of Pathology - ajp.amjpathol.orginvolve the CREB1 response element found in the upstream
region of Hdac6 promoter, in combination with the patho-
logical increased intracellular levels of cAMP described in
polycystic diseases, which would ultimately activate PKA-
CREB1 cascade and HDAC6 expression.1,13,26,33,34 Other
possibilities are increased half-life of HDAC6 protein or
decreased expression of speciﬁc microRNAs targeting
HDAC6 mRNA, as previously described to be the case for
CDC25A.27
Our ﬁndings that both human ADPKD and PCK rat
cholangiocytes respond to HDAC6 inhibition by Tubastatin-
A, Tubacin, and ACY-1215 with reduced proliferation,
indicate HDAC6 dysregulation may be indeed important for
cyst growth. Furthermore, the three-dimensional culture
system, in which bile ducts isolated from the PCK rat are
treated with Tubastatin-A and Tubacin, showed a signiﬁcant
decrease in cyst development, which encouraged our in vivo
studies with the orally bioavailable, recently developed,
HDAC6 inhibitor, ACY-1215, demonstrating its potential as
a therapeutic approach for PLDs.
In an attempt to ﬁnd potential new drugs capable of
attenuating PKD, the HDAC pan-inhibitor TSA and the class
I HDAC inhibitor VPA showed efﬁcacy in the kidney
phenotype of animal models of PKD; however, no infor-
mation on PLD or human cystic cells were available until
now.17,18 TSA and VPA are known to target multiply
HDACs, which makes it difﬁcult to determine whether the
observed effect was due to the inhibition of one or more
HDACs, even though one of these studies suggested HDAC1
as the main player.17 Our study is the ﬁrst to test HDAC6
speciﬁc inhibitors in PLD models, implicating that HDAC6
may be an attractive molecular target in this disease.605
Gradilone et alThere has been considerable progress in unraveling the
complex molecular events responsible for cyst formation
and growth in PLD.1,13,15,26e28,34e38 Our ﬁndings place
HDAC6 among the already established molecules and
pathways that are dysregulated in PLD. HDAC6 has not
been previously linked to PLD; however, overexpression of
HDAC6 has been reported in multiple tumors including
cholangiocarcinoma. Indeed, the HDAC6 inhibitor,
Tubastatin-A, is able to reduce cholangiocarcinoma growth
in vitro and in vivo while restoring the expression of primary
cilia in tumor cells.20 Because the PLDs can be considered a
benign hyperproliferative condition,39,40 and increased cell
proliferation, as well as ciliary distortion, malformation and
loss are common features of polycystic diseases,1,16,26,41,42
our data suggest that HDAC6 might play a critical role in
PLD pathogenesis.
Due to the involvement of HDACs in cancer, several
inhibitory molecules have been developed and extensively
tested. Among them, vorinostat (suberoylanilide hydroxamic
acid) has been approved in cutaneous T-cell lymphoma,43 and
TSA and VPA suppressed kidney cyst formation in animal
models of PKD.17,18 Our ﬁndings are consistent with these
previous studies, suggesting HDAC inhibitors could be
explored as therapeutic agents for the treatment of polycystic
diseases. Here, we propose to speciﬁcally target HDAC6,
which would have less undesirable secondary effects, for the
treatment of polycystic liver diseases. Wild-type zebraﬁsh
treated with the HDAC pan-inhibitor TSA, the class I speciﬁc
inhibitor VPA, or hdac1 morpholinos, induced curve body
axis, light pigmentation, abnormal pectoral ﬁn formation, and
pericardic edema. On the other hand, hdac6 morpholinos
failed to produce such phenotypes.17 This suggests the use of
HDAC6 speciﬁc inhibitors for PKD treatment would poten-
tially have less deleterious secondary effects in comparison
with the broader effects induced by pan-HDACs inhibitors.
Furthermore, in contrast to HDAC1, -2, -3, -4, -7, and -8,
HDAC6knock-outmice are viable and fertile,44,45 supporting
the concept that treatment with HDAC6-speciﬁc inhibitors
will have minimal adverse effects. In fact, our in vivo exper-
iment demonstrated no obvious toxic effect in treated animals
and suggests that the pharmacological inhibition of HDAC6
byACY-1215 could be a potential novel therapeutic approach
for PLDs.
HDAC6 has at least ﬁve known targets (ie, a-tubulin,
b-catenin, cortactin, heat-shock-protein 90, and the redox
regulatory proteins PrxI and PrxII).19,20,30 Herein, we as-
sessed two targets that may be related to cystogenesis: acet-
ylated-a-tubulin (major ciliary component) and b-catenin.
The abnormal activation of the Wnt/b-catenin pathway,
resulting in nuclear accumulation of b-catenin, is character-
istic in polycystic kidney disease.46e49 It has been reported
that b-catenin nuclear localization is regulated by HDAC6-
dependent deacetylation in the colon cancer cell line
HCT116. b-catenin deacetylation inhibits its degradation
leading to accumulation in the cytosol and nuclear trans-
location, where it activates pro-proliferative genes such as606c-myc and cyclinD1.19 Our data showing a decreased expres-
sion of b-catenin induced by HDAC6 inhibitors suggest
b-catenin may be involved in PLD pathogenesis, consistent
with the recent study by Spirli et al49 using ﬁbrocystin-
defective cholangiocytes. Furthermore, our data show that
HDAC6 inhibition reduces the b-catenin target gene products,
c-myc and cyclin D1. Nevertheless, we acknowledge that our
data suggesting that decreased cystic growth induced by
HDAC6 inhibition is related to the degradation of b-catenin
needs further study, in particular because, in addition to
b-catenin, HDAC6 has multiple other targets, as noted above,
that may also be involved in cyst growth regulation. Further-
more, b-catenin can also be phosphorylated at Ser-552 and
Ser-675 by PKA.49 The phosphorylation at these sites induces
the activity of b-catenin rather than degradation, and the
possibility that HDAC6 inhibition may also affect these
phosphorylation sites cannot be excluded.
Our study identiﬁed HDAC6 as a new molecular target in
cystic cholangiocytes, which can be selectively inhibited
and subsequently decreasing cell proliferation and cyst
growth by affecting downstream signaling known to be
involved in the cystic diseases. Our in vitro data, and our
in vivo studies with the recently developed ACY-1215,31
which is now in clinical trials for multiple myeloma, sug-
gest that the pharmacological inhibition of HDAC6 may be
a potential therapeutic approach for patients with PLD,
including ADPKD and ARPKD.
In Summary, HDAC6 is overexpressed in cholangiocytes
derived from the PCK rat, liver cysts of the PCK rat, and
ADPKD and ARPKD patients. Selective inhibitors of
HDAC6, Tubastatin-A, Tubacin, and ACY-1215 decrease
cell proliferation in cholangiocytes derived from the PCK
rat and human patient with ADPKD and reduce cyst growth
in vitro and in vivo. The data are suggestive of the possi-
bility that degradation of b-catenin may be a potential
mechanism for the decreased cyst growth induced by
HDAC6 inhibition, although further analysis is warranted.
Taken together, our data identiﬁed HDAC6 as a new mo-
lecular target in polycystic liver disease and implicates the
potential use of HDAC6 inhibitors in the treatment of PLD.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.11.027.
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